Introduction
Lutetium-177 PSMA therapy (Lu-177 PSMA) is an advanced form of targeted radionuclide treatment used for selected patients with advanced prostate cancer.
It belongs to a treatment class known as radioligand therapy, which delivers radiation directly to cancer cells while limiting exposure to healthy tissues.
This therapy targets prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells, particularly in advanced and metastatic disease.
By binding to PSMA-positive cells and delivering localized radiation, Lu-177 PSMA can reduce tumor burden and control disease progression.
Türkiye is a trusted destination for advanced nuclear medicine therapies, offering experienced specialists, modern treatment facilities, and integrated oncology care.
Averia Health supports international patients through ethical, structured, and fully coordinated Lutetium-177 PSMA therapy focused on safety, accuracy, and continuity of care.
Why Choose Türkiye for Lutetium-177 PSMA Therapy
Türkiye is internationally recognized for advanced prostate cancer treatment because of:
- Experienced nuclear medicine physicians and oncologists
- Availability of Lutetium-177 radioligand therapy
- Advanced nuclear medicine treatment units
- Multidisciplinary prostate cancer care teams
- Strict radiation safety and quality assurance protocols
- Internationally accredited hospitals
Türkiye combines cutting-edge targeted therapy with comprehensive oncologic care.
Why Choose Averia Health
Averia Health provides structured coordination for Lu-177 PSMA therapy:
- Pre-arrival review of medical history, pathology, and imaging
- Coordination of PSMA PET-CT eligibility assessment
- Referral to experienced nuclear medicine therapy centers
- Multidisciplinary coordination (urology, oncology, nuclear medicine)
- Clear explanation of treatment goals, benefits, and limitations
- Professional interpreter services
- 24/7 patient support during your stay
- Post-therapy follow-up and international care coordination
Our approach prioritizes ethical practice, patient safety, and informed decision-making.
Who Is a Candidate for Lutetium-177 PSMA Therapy
Lu-177 PSMA therapy may be considered for patients with:
- Advanced or metastatic prostate cancer
- Castration-resistant prostate cancer (CRPC)
- PSMA-positive disease confirmed on PSMA PET-CT
- Disease progression despite standard therapies
- Adequate bone marrow, kidney, and liver function
Final eligibility is determined through comprehensive evaluation.
Diagnostic Evaluation Before Therapy
Before treatment, patients typically undergo:
- PSMA PET-CT scan to confirm PSMA expression
- Blood tests (kidney, liver, bone marrow function)
- Review of prior prostate cancer treatments
- Oncology and nuclear medicine consultation
- Assessment of overall health and treatment suitability
Accurate selection ensures safety and treatment effectiveness.
Lutetium-177 PSMA Therapy Procedure
Radioligand Administration
Lutetium-177 PSMA is administered intravenously under controlled conditions.
Targeted Radiation Delivery
The radioligand binds to PSMA-expressing cancer cells and delivers localized radiation.
Post-Treatment Monitoring
Patients are monitored for side effects and radiation safety compliance.
The procedure is performed by experienced nuclear medicine teams following strict safety protocols.
Treatment Journey in Türkiye
- Pre-Arrival Case Review
Medical records, imaging, and laboratory results are reviewed. - Eligibility Confirmation
PSMA PET-CT and clinical assessment confirm suitability. - Personalized Treatment Planning
Therapy plan and expectations are discussed clearly. - Lutetium-177 PSMA Therapy
Treatment is administered in a specialized nuclear medicine unit. - Post-Therapy Care & Monitoring
Side effects and laboratory values are monitored. - Follow-Up & Oncologic Continuity
Ongoing care and international follow-up are coordinated.
Expected Results & Benefits
- Targeted treatment of PSMA-positive prostate cancer
- Reduction in tumor activity and disease burden
- Symptom relief in selected patients
- Improved disease control in advanced cases
- Treatment option when conventional therapies are limited
Response varies depending on disease stage and individual factors.
Risks & Considerations
Lutetium-177 PSMA therapy is generally well tolerated but may involve:
- Fatigue
- Dry mouth (xerostomia)
- Temporary blood count suppression
- Nausea or mild discomfort
- Need for repeated treatment cycles in some cases
All risks are discussed thoroughly before treatment.
What’s Included in Your Medical Trip
- Pre-therapy consultations and eligibility evaluation
- PSMA PET-CT coordination (if required)
- Lutetium-177 PSMA therapy
- Nuclear medicine and hospital services
- Post-therapy monitoring and medications
- Interpreter services
- 24/7 patient support
- International oncology follow-up coordination
Averia Health ensures ethical, precise, and patient-centered radioligand therapy care.
Frequently Asked Questions
Is Lutetium-177 PSMA chemotherapy?
No. It is a targeted radioligand therapy, not chemotherapy.
Do all prostate cancer patients qualify?
No. PSMA expression and clinical criteria must be met.
Is the treatment safe?
Yes, when performed in specialized centers with proper monitoring.
Will I need more than one treatment?
Some patients receive multiple cycles based on response and tolerance.
Can follow-up continue after returning home?
Yes. International follow-up and coordination are provided.
Ready to Start Your Health Journey?
Access advanced, targeted prostate cancer treatment with Lutetium-177 PSMA therapy in Türkiye.
Request a case review or contact us on WhatsApp to speak with our oncology coordination team.
